This Viewpoint describes reforms to the ways the National Health Service (NHS) appraises cost-effectiveness and coverage of cancer drugs in England and Wales, the role of the National Institute for Health and Care Excellence (NICE) in the process, and changes in drug approval rates and access to new drugs as a result.
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2BIhWGd
via IFTTT
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
Abstract Cerebral and systemic organ microvascular pathologies coexist with human Alzheimer’s disease (AD) neuropathology. In this study, w...
-
Abstract Over the past decades, an increasing need in renewable resources has progressively appeared. This trend concerns not only fossil f...
-
Zeinab Nazeeh Shata, Marwa R Amin, Heba M El-Kady, Mervat W Abu-Nazel Avicenna Journal of Medicine 2017 7(2):54-63 Background: Unlike ot...
-
Abstract Background Henoch–Schönlein purpura is the most common vasculitis in children. Its long-term prognosis depends on renal involve...
-
by Kenichiro Motomura, Naoko Okada, Hideaki Morita, Mariko Hara, Masato Tamari, Keisuke Orimo, Go Matsuda, Ken-Ichi Imadome, Akio Matsuda, T...
-
Abstract Purpose Identifying the elbow flexion–extension (F–E) movement axis is important for placing a hinged elbow external fixator. A...
-
A descriptive study of clinical and radiological profile of longitudinal extensive myelitis in a tertiary hospital in Rajasthan, India Publi...
-
Abstract The production of biofuels from microalgae is a promising and sustainable alternative. Its production is determined by the content...
-
Lippincott Journals Monthly Update: Otolaryngology Case Studies Comparing Learning Profiles and Response to Instruction in Autism Spectrum...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου